Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-009 in recurrent or metastatic triple-negative breast cancer
2019-001892-35Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, pembrolizumab, carboplatin and gemcitabine in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Sep 2019; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2019-001892-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001892-35.